普译生物

星辰海医疗成立于2020年10月，是一家专注于内窥镜介入诊疗业务的医疗科技公司，旨在向全球提供涵盖泌尿、呼吸、消化等科室的内窥镜介入诊疗整体解决方案，让疾病更早被发现，让患者更好被治疗。内窥镜诊疗是非血管微创介入的重要组成部分，广泛分布于消化科、泌尿科、呼吸、耳鼻喉科、普外科以及妇科等。

Cytovale是一个由生物学家，数据科学家和工程师组成的团队，致力于开发机械生物标志物以改善人类健康。 Cytovale的新型微流体平台允许 Cytovale,Inc探测单个细胞以量化疾病的机械特征。 Cytovale首先将其应用于败血症，这种疾病的早期检测可显着改善患者预后并降低治疗成本。

Billiontoone Inc is a developer of a molecular counter platform intended to improve the resolution of cell-free DNA testing. The company's prenatal testing procedure focuses on quantitative biology and statistical learning methods to optimize the signal-to-noise ratio and detect single-gene disorders, enabling expecting mothers to detect disorders such as sickle-cell disease, beta-thalassemia, spinal muscular atrophy, and cystic fibrosis through a simple blood test.In December 2022, Billiontoone Inc announces it has secured an additional $48.5 million of funding from existing equity investors as well as upsized its Term Loan Facility with access to up to $35 million With this additional funding, gross proceeds will reach $280 million.In March 2022, BillionToOne Inc closed an oversubscribed Series C funding round of $125 million with premier global investors